CN118369331A - Caix靶向型il-12融合蛋白及其使用方法 - Google Patents

Caix靶向型il-12融合蛋白及其使用方法 Download PDF

Info

Publication number
CN118369331A
CN118369331A CN202280076070.8A CN202280076070A CN118369331A CN 118369331 A CN118369331 A CN 118369331A CN 202280076070 A CN202280076070 A CN 202280076070A CN 118369331 A CN118369331 A CN 118369331A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
polypeptide
seq
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280076070.8A
Other languages
English (en)
Chinese (zh)
Inventor
佳亚·巴特纳格尔
阿尔温德·维塔尔·戈斯瓦米
哈里什·库玛·特利普拉那
普拉迪普·奈尔
拉马克里希南·梅拉科德·萨巴拉曼
希夫·拉姆·奎师那
斯里尼瓦·雷迪·博瑞迪
瑞希米·奈尔
艾瓦尼斯·K·瓦什尼
谭申来
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bikala Treatment Co ltd
Original Assignee
Bikala Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bikala Treatment Co ltd filed Critical Bikala Treatment Co ltd
Publication of CN118369331A publication Critical patent/CN118369331A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202280076070.8A 2021-09-17 2022-09-16 Caix靶向型il-12融合蛋白及其使用方法 Pending CN118369331A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245523P 2021-09-17 2021-09-17
US63/245,523 2021-09-17
PCT/US2022/043762 WO2023043978A2 (en) 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
CN118369331A true CN118369331A (zh) 2024-07-19

Family

ID=85603506

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280076070.8A Pending CN118369331A (zh) 2021-09-17 2022-09-16 Caix靶向型il-12融合蛋白及其使用方法

Country Status (11)

Country Link
US (1) US20240392031A1 (https=)
EP (1) EP4402158A4 (https=)
JP (1) JP2024534468A (https=)
KR (1) KR20240161081A (https=)
CN (1) CN118369331A (https=)
AU (1) AU2022345103A1 (https=)
CA (1) CA3232632A1 (https=)
IL (1) IL311442A (https=)
MX (1) MX2024003275A (https=)
WO (1) WO2023043978A2 (https=)
ZA (1) ZA202402034B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111630062A (zh) 2017-11-28 2020-09-04 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
WO2025012105A2 (en) * 2023-07-07 2025-01-16 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Muteins of human interleukin 12
WO2025101133A1 (en) * 2023-11-10 2025-05-15 Agency For Science, Technology And Research Interleukin-12 variants and medical uses thereof
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
WO2025205534A1 (ja) * 2024-03-25 2025-10-02 積水メディカル株式会社 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620648B1 (pt) * 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
IL297186A (en) * 2020-04-17 2022-12-01 Univ Leland Stanford Junior Transgenic il-12 and il-23 polypeptides and their uses

Also Published As

Publication number Publication date
CA3232632A1 (en) 2023-03-23
MX2024003275A (es) 2024-05-07
EP4402158A4 (en) 2025-07-30
AU2022345103A1 (en) 2024-03-28
WO2023043978A3 (en) 2023-09-28
US20240392031A1 (en) 2024-11-28
ZA202402034B (en) 2025-06-25
KR20240161081A (ko) 2024-11-12
WO2023043978A2 (en) 2023-03-23
JP2024534468A (ja) 2024-09-20
IL311442A (en) 2024-05-01
EP4402158A2 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US20240392031A1 (en) Caix targeting il-12 fusion proteins and methods of use thereof
JP6571527B2 (ja) 二重特異性抗体
CN114560941B (zh) Cldn18.2的抗体及其应用
JP2020530296A (ja) 血清中半減期の増強のための操作された抗体ｆｃバリアント
JP2019533475A (ja) 抗ｃｔｌａ４−抗ｐｄ−１二機能性抗体、その医薬組成物および使用
CN104884617A (zh) 抗folr1抗体
WO2020244528A1 (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
KR20070114765A (ko) 생물학적 활성을 조절하기 위한 이특이성 결합제
US20210107961A1 (en) Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15
US20230364255A1 (en) Transglutaminase-mediated conjugation
US20240376198A1 (en) NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
EP4646439A1 (en) Antigen-binding molecules
WO2023004305A1 (en) Cd8-targeted modified il-2 polypeptides and uses thereof
US20240228620A1 (en) Multispecific proteins and related methods
US20250333464A1 (en) Il10 agonists and methods of use thereof
WO2022116079A1 (zh) 一种抗ceacam5的人源化抗体及其制备方法和用途
US20260008847A1 (en) Anti-lilrb2 antibodies and uses thereof
HK40114345A (zh) Caix靶向型il-12融合蛋白及其使用方法
US20250197507A1 (en) Cd161 binding proteins and related methods
HK40121523A (zh) 多特异性蛋白及相关方法
EP4725970A1 (en) Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody
WO2025072871A2 (en) ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
CN121758624A (zh) 结合人cd16和/或人cd123的多种抗体及其用途
WO2025075858A2 (en) ANTI-IL13Rα2 ANTIBODY COMPOSITIONS AND USES THEREOF
WO2024141014A1 (zh) Cd74的医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40114345

Country of ref document: HK